Literature DB >> 1983772

D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates.

J Brandt1, S E Folstein, D F Wong, J Links, R F Dannals, A McDonnell-Sill, S Starkstein, P Anders, M E Strauss, L E Tune.   

Abstract

The relationship of dopamine receptor binding in the caudate nucleus and the putamen to neurological and neuropsychological functioning was examined in 21 patients with Huntington's disease (HD) and eight individuals at risk of developing Huntington's disease. A significant reduction in relative binding of [11C]3-N-methylspiperone to the dopamine receptor was found in both the caudate and putamen of HD patients. Binding in the caudate was correlated only with tests of rapid coding and set alternation, while binding in the putamen was correlated only with duration of illness. The findings indicate that the well-described atrophic changes in the striatum of Huntington's disease patients are accompanied by receptor alterations. They also support previous animal and human studies indicating that the caudate nucleus plays a larger role in cognition than in motor functions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1983772     DOI: 10.1176/jnp.2.1.20

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  8 in total

Review 1.  Parallel distributed processing and neuropsychology: a neural network model of Wisconsin Card Sorting and verbal fluency.

Authors:  R W Parks; D S Levine; D L Long; D J Crockett; I E Dalton; H Weingartner; P Fedio; K L Coburn; G Siler; J R Matthews
Journal:  Neuropsychol Rev       Date:  1992-06       Impact factor: 7.444

Review 2.  The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.

Authors:  Ignacio Munoz-Sanjuan; Gillian P Bates
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 3.  Brain imaging and cognitive dysfunctions in Huntington's disease.

Authors:  Alonso Montoya; Bruce H Price; Matthew Menear; Martin Lepage
Journal:  J Psychiatry Neurosci       Date:  2006-01       Impact factor: 6.186

4.  Extrastriatal dopamine D(2) receptor binding in Huntington's disease.

Authors:  Mouna Esmaeilzadeh; Lars Farde; Per Karlsson; Andrea Varrone; Christer Halldin; Susanna Waters; Joakim Tedroff
Journal:  Hum Brain Mapp       Date:  2010-09-30       Impact factor: 5.038

5.  Monitoring Huntington's disease progression through preclinical and early stages.

Authors:  Chris Tang; Andrew Feigin
Journal:  Neurodegener Dis Manag       Date:  2012-08-01

6.  Dopamine D1 receptor number--a sensitive PET marker for early brain degeneration in Huntington's disease.

Authors:  G Sedvall; P Karlsson; A Lundin; M Anvret; T Suhara; C Halldin; L Farde
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

7.  Plasma homovanillic acid and prolactin in Huntington's disease.

Authors:  Manolis Markianos; Marios Panas; Nikos Kalfakis; Dimitrios Vassilopoulos
Journal:  Neurochem Res       Date:  2008-10-08       Impact factor: 3.996

Review 8.  Neuroimaging in Huntington's disease.

Authors:  Flavia Niccolini; Marios Politis
Journal:  World J Radiol       Date:  2014-06-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.